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Abstract
The effects of the drugs Losartan, Enalapril and their combination on the hemodynamics and morphofunctional parameters of the heart 
were studied in 80 patients with chronic heart failure (CHF) of II-IV functional class and the ejection fraction of the left ventricle less then 45% 
which worsened the ischemic cardiopathia.  It was established that after a 24-week therapy with each drug and their combination, there was a 
decrease in symptoms in every group, but more so in the group that took the combined therapy.  Along with the symptoms, there was also a 
decrease in the functional class of the chronic heart insufficiency by 16.4% of those who took Losartan, by 15.5% of those who took Enalapril and 
by 19.9% of those who took the combined therapy.  The treatment with Losartan increased the fraction of ejection of the left ventricle by 14.9%, 
with Enalapril by 8.9% and with both drugs by 21.4%.  It was established that the combined therapy, which included Losartan and Enalapril, had 
a better impact on the parameters of the myocardium remodeling then these drugs taken seperately.
Key words: chronic heart failure, ischemic cardiopathy, Losartan, Enalapril, myocardium remodeling.
Влияние лозартана, эналаприла и их комбинации на функцию сердца
У 80 пациентов с хронической сердечной недостаточностью II-IV функциональных классов и фракцией выброса левого желудочка 
менее 45% с осложнением ишемической болезни сердца изучали влияние препаратов лозартан, эналаприл и их сочетание на 
гемодинамические и морфофункциональные параметры сердца.  Было установлено, что после 24-недельного курса лечения, все схемы 
терапии привели к улучшению симптоматической картины в каждой группе, но больше в группе, которая принимала комбинированную 
терапию.  Произошло уменьшение функционального класса хронической сердечной недостаточности на 16,4% под влиянием Лозартана, 
на 15,5% – Эналаприла и 19,9% – комбинированной терапии.  Лечение лозартаном увеличило долю выброса левого желудочка на 
14,9%, Эналаприлом – на 8,9%, а обоими препаратами – на 21,4%.  Было установлено, что комбинированная терапия, которая включала 
Лозартан и Эналаприл, имела более эффективное воздействие на параметры ремоделирования миокарда.
Ключевые слова: хроническая сердечная недостаточность, ишемическая болезнь сердца, Лозартан, Эналаприл, ремоделирование 
миокарда.
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Introduction
Chronic heart failure (CHF) is a syndrome caused by di-
sorders of neurohumoral regulation of the circulatory system, 
accompanied by systolic and/or diastolic function disorders 
manifested by blood stagnancy in the large and small circula-
tory systems [1].  Chronic heart failure is a complication of al-
most all cardiovascular diseases, coronary heart disease being 
the most frequent [3].  CHF is one of the most frequent causes 
of hospitalization in developed countries, especially in patients 
of older age groups.  Patients hospitalized for decompensated 
heart failure are at high risk of repeated hospital admissions, 
the frequency of which reaches 50% within 6 months after 
discharge and within one year re-hospitalization reaches 
68% of patients with chronic heart failure [3, 4].  According 
to the modern neurohumoral concepts of the pathogenesis, 
the primary role in the development of CHF is given to the 
sympathetic-adrenal (NAC) and its opposing system of the 
atrial natriuretic factor (PNF).  This fact justifies the use of 
different neurohormonal modulators (NGM), including ACE 
inhibitors and AT receptor antagonists I in the treatment of pa-
tients with CHF [3, 4].  ACE inhibitors were the first group of 
drugs acting directly on the RAAS and used in a broad clinical 
practice [2].  By reducing the activity of RAAS and activating 
the system of bradykinin, ACE inhibitors have important 
anti-remodeling, vasodilating, diuretic and antiproliferative 
effects [3].  The harmonious combination of efficacy and safety 
has allowed this class of drugs to gain a worthy place in the 
treatment of patients with CHF.  However, numerous clinical 
studies have shown that monotherapy can effectively control 
the symptoms of CHF in a small number of patients.  This is 
due to the many factors of CHF and the multiple pathogenetic 
components involved in its development.
The period of formation and progression of CHF and its 
severity is defined in the majority of patients by well-timed 
and adequately matched pharmacotherapy.  Detailed analysis 
of the pathogenetic model of formation and development of 
CHF may help in developing differentiated approaches to 
pharmacotherapy of this disease adapted to the pathogenic 
and clinical course of CHF in each specific patient.  In the 
literature, the impact of individual drugs on various para-
meters and cardiac function of patients with CHF is covered 
pretty adequately [1, 2], but few studies have examined the 
possibility of combined therapy between ACE inhibitors and 
antagonists of AT I - receptors of the CHF.
Aim of the study - to evaluate the influence of AT I re-
ceptor antagonist Losartan, ACE inhibitor Enalapril and their 
combination on the clinical manifestations, hemodynamics 
and morphofunctional parameters of the heart in patients 
with chronic heart failure as a complication of chronic heart 
disease.
Materials and methods
The study included 80 patients with stable symptomatic 
CHF II-IV FC (classification of New York Association of 
Cardiologists - NYHA) and LV EF ≤ 45% as complication 
of CHF.  Among the examined patients 77.5% were male 
and 22.5% - women aged 48 to 72 years (average age being 
62.2 ± 8.4 years).  42 patients were diagnosed with CHF II 
FC, 21 - III FC, 17 patients - CHF IV FC.  All patients have 
suffered an acute myocardial infarction (AMI) no earlier 
than 6 months before the study and had a clinically expressed 
angina pectoris I-III FC.  Angina of I FC was diagnosed in 
20 patients, II FC - in 47 patients, III FC - in 13 patients, the 
average angina pectoris CF value was 1.88 ± 0.2.  The average 
duration of CHF was 8.83 ± 2.42 years.  Presence of old MI 
was confirmed by ECG and echocardiography data.  CHF 
duration ranged from 6 months to several years and averaged 
54.8 ± 13.2 months.  All patients with CHF showed a decrease 
of contractile function of LV myocardium, left ventricular 
ejection fraction averaged 42.7 ± 1.89%.  CHD developed on 
the background of arterial hypertension (AH) in 39 patients 
(48.7%).  All patients with CHF were divided into 3 groups: 
group 1 (26 patients) received Losartan at a dose of 50-100 mg 
once a day, group 2 (27 patients) - Enalapril 5-10 mg twice a 
day and group 3 (27 patients) - a combination consisting of 
Losartan and Enalapril.  Duration of treatment was 24 weeks. 
All the patients were administered the standard therapy for 
CHF consisting in diuretics, antiagregants and, if necessa-
ry, cardiac glycosides and peripheral vasodilator - nitrates. 
37.5% of patients received digoxin in a dose of 0.125 – 0.5 
mg/day, 29 (36.2%) patients received hypothiazide 12.5 - 50 
mg 1 time per day, 10 (12.5%) patients - Furosemide 1 mg/
day 2-3 times a week.  Evaluation of the effectiveness of the 
drugs and their combination included the examination of the 
dynamics of clinical manifestations of CHF, the tolerance to 
everyday physical activities, hemodynamic parameters - heart 
rate, systolic and diastolic blood pressure (mm Hg).  Systolic 
function was assessed according to the value of LV EF and 
the degree of shortening of the anteroposterior size of the left 
ventricle in systole, diastolic function - highest peak velocity 
of early filling (PVEF), peak velocity of late filling (PVLF), 
modulus of elasticity (ME) and stiffness (MS).  Morpholo-
gical and functional cardiac parameters were assessed using 
echocardiography: by determining the size of the left atrium 
(LA, cm), end diastolic (EDD, cm) and end systolic (ESD cm) 
dimensions, LV ejection fraction (EF) in %.  The tolerance to 
physical exertion in patients with CHF was assessed by bicycle 
stress test with the determination of the total performed work 
(TPW, W) and duration of load. Clinical and instrumental 
examinations were performed before treatment and after 
12 and 24 weeks of therapy with Losartan, Enalapril and 
their combination.  To assess the safety of the treatment, it 
was carried out a laboratory exam with an analysis of blood 
potassium and creatinine before treatment and after 12 and 
24 weeks of treatment.
Statistical data analysis was carried out using standard 
methods of statistics, including the calculation of the unpaired 
Student-t criteria.  All data are presented as mean standard 
deviation (M ± m). The difference was considered statistically 
significant at p < 0.05.
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significance of the decrease of FC was different in every sur-
veyed group. Thus, after 12 weeks of treatment with Losartan 
the FC decreased by 9.1% (p < 0.05), with Enalapril - by 7.2% 
(p > 0.1) and the treatment with the combination of drugs – by 
13.9% (p < 0.01), by the end of 24 weeks the FC decreased by 
16.4%, 13.5% and 19.9% respectively (p < 0.001, p <0.05, p < 
0.001). The dynamics of the FC under the influence of various 
schemes of pharmacotherapy is shown in pic. 1.
The influence of both drugs and their combination on 
heart rate and blood pressure in patients with chronic heart 
failure as a complication of CHD was approximately the 
same.  Thus, heart rate before treatment with Losartan was 
78.1 ± 12.5 bpm, with Enalapril – 79.5 ± 11.2 and with the 
combination of drugs – 78.3 ± 12.4 bpm.  After 24 weeks of 
treatment significant changes in the heart rate were not ob-
served in either group 78.7 ± 11.2; 74.4 ± 9.0 and 76.3 ± 12.1 
bpm, respectively.
Receiving Losartan contributed to a reducing of SBP and 
decreasing of DBP from 92.4 ± 4.2 to 78.5 ± 4.0 mm Hg, while 
Table 2
The evolution of the LV systolic function (M ± m)
Indices
Examined groups
I (n = 26) II (n = 27) III (n = 27)
Initial values 24 weeks later Initial values 24 weeks later Initial values 24 weeks later
LV EF, %
% DS
44.2 ± 0.92
28.1 ± 0.73
50.8 ± 0.87***
31.5 ± 0.74**
44.5 ± 0.94
28.3 ± 0.87
46.4 ± 0.95
30.1 ± 0.73
42.4 ± 0.87
27.9 ± 0.54
51.5 ± 0.71***
23.8 ± 0.68***
Note: ** - p < 0.01; *** - p < 0.001 - statistically significant differences in performance between the initial and 24 weeks later values.
Table 3
The evolution of the LV diastolic function (M ± m)
Indices
Examined groups
I (n = 26) II (n = 27) III (n = 27)
Initial values 24 weeks later Initial values 24 weeks later Initial values 24 weeks later
PVEF, cm х sec
PVLF, cm х sec
ME, c.u.
MS, c.u.
57.8 ± 1.14
54.4 ± 1.31
4.21 ± 0.18
3.30 ± 0.23
63.1 ± 1.15**
51.3 ± 1.14
3.90 ± 0.16
2.91 ± 0.12
58.1 ± 1.13
54.7 ± 1.21
4.09 ± 0.19
3.20 ± 0.24
61.4 ± 1.17*
53.2 ± 1.30
3.93 ± 0.21
3.01 ± 0.28
57.2 ± 0.84
55.4 ± 0.91
4.20 ± 0.15
3.20 ± 0.14
65.1 ± 0.95***
50.4 ± 0.88**
3.70 ± 0.14*
2.70 ± 0.13*
Note: * - p < 0.05; ** - p < 0.001; *** - p < 0.001 - statistically significant differences in performance between the initial and 24 weeks 
later values.
Table 1
The dynamics of clinical manifestations of CHF under the influence of Losartan therapy, Enalapril and their combination
Clinical symptoms
Group I (n = 26) Group II (n = 27) Group III (n = 27)
Initial values 12 weeks later
24 weeks 
later Initial values
12 weeks 
later
24 weeks 
later Initial values
12 weeks 
later
24 weeks 
later
Dyspnea in physical effort 26100%
15
57.7%
10
38.5%
27 
100 %
18
66.6%
12
44.4%
27 
100%
15 
55.5%
8
29.6%
Dyspnea at rest 3 11.5%
2 
7.7%
1
3.8%
2 
7.4%
2 
7.4%
0
0%
2 
7.4%
1 
3.7%
0
0%
Weakness 2284.6%
13 
50.0%
10
38.5%
23
85.2%
14
51.8%
13 
48.1%
21
77.7%
13
48.1%
8
29.6%
Palpitations 1765.4%
12
46.2%
9
34.6%
17
63.0%
16 
59.3%
12
44.4%
17 
62.9%
10
37.0%
5
18.5%
Acrocyanosis 623.1%
3 
11.5%
1
3.8%
6 
22.2%
3 
11.1%
0
0%
8
29.6%
7
25.9%
1 
3.7%
Peripheral swelling 2076.9%
13 
50.0%
11
42.3%
22
81.5%
15 
55.5%
13
48.1%
25
92.6%
17
62.9% 829.6%
Results and discussion
Analysis of clinical manifestations of the disease showed 
that after 24 weeks of treatment in all patients with CHF, 
there was a decrease of dyspnea and weakness, an increase 
in tolerance to daily stress, but it should be noted that in the 
group of patients treated with the drug combination consisting 
of losartan and enalapril, the positive dynamics of clinical 
symptoms of CHF was more pronounced than in case of 
monotherapy (tab. 1).
The data presented in table 1 reveals that after 24 weeks 
of treatment with Losartan the dyspea diminished by 2.6 ti-
mes, with Lisinopril – 2.2 times, with the combined therapy 
– by 3.4 times.  In all three groups the administered therapy 
contributed to a diminishing or disappearance of peripheral 
edemas: in the patients of the I and II groups this manifestation 
diminished by 1.8 and 1.7 times, while in the III group – by 
3.1 times in comparison with the original data.
The results of the study confirmed that the positive dyna-
mics of clinical symptoms of CHF  reduced the FC, but the 
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* - р < 0.05 – statistically significant differences in performance 
between the initial and 24 weeks later values.
Fig. 1.  The dynamics of the FC under the influence  
of various schemes of pharmacotherapy.
a more significant reduction in blood pressure was found in 
patients with concomitant hypertension.  During the treat-
ment with Enalapril SBP decreased by 6.6% from 135.8 ± 5.2 
to 126.8 ± 3.9 mmHg (p > 0.1) and DBP by 5.4% from 85.2 
± 9.3 to 80.6 ± 8.7 mm Hg (p > 0.1).  The medium arterial 
pressure decreased from 102.3 ± 10.8 to 96.0 ± 10.2 mm Hg 
or by 8.9% (p > 0.1).  When treating with the combination of 
drugs including Losartan and Enalapril after 24 weeks there 
is was a significant decrease in SBP from 136.2 ± 4.2 to 123.5 
± 4.1 mm Hg by 9.3%, (p < 0.05), DBP – by 7.9% from 96.3 
± 3.7 down to 79.5 ± 3.5 (p < 0.01).
Ejection fraction of LV in patients with CHF before treat-
ment was approximately the same in either group (tab. 2).
Treatment with Losartan during 24 weeks led to an incre-
ase in LV EF by 14.9% (p < 0.001), with Enalapril - by 4.3% 
(p > 0.1), with the combined therapy - by 21.4% (p < 0.001).
The evolution of the LV diastolic function during the 
applied therapy in the examined groups is presented in tab. 3.
Data from tab. 3 shows that monotherapy with Losartan 
and Enalapril contributed to an increase in peak velocity of 
early filling (PVEF) by 9.2% and 5.6% respectively, whereas 
their combination resulted in an increase of the same parame-
ter by 13.8%.  In patients treated with Losartan and Enalapril 
Table 4
Indicators of cardiac remodeling in patients with CHF before and after treatment
Indicator
Examined groups
I (n = 26) II (n = 27) III (n = 27)
Initial values 24 weeks later Initial values Initial values 24 weeks later Initial values
LVMMI, g/m²
RTW, %
TPVR,din*s*cm-5
EDPLV, mm Hg
135.2 ± 6.8
47.0 ± 1.3
2187.7 ± 86.2
12.4 ± 0.9
118.2 ± 7.2
43.0 ± 1.2*
1862.0 ± 109.0*
11.0 ± 1.1
141.1 ± 9.7
46.9 ± 3.0
2063.6 ± 80.5
11.9 ± 1.1
120.1 ± 9.7
45.0 ± 3.0
2009.1 ± 106.3
13.0 ± 0.9
137.5 ± 5.6
47.1 ± 1.2
2103.9 ± 84.9
12.2 ± 0.8
116.0 ± 5.3**
40.8 ± 0.9***
1683.1 ± 107.2**
9.1 ± 1.0*
Note: LVMMI - left ventricular myocardium mass index; RWT - relative wall thickness; TPVR - total peripheral vascular resistance; 
EDPLV - end diastolic pressure in the left ventricle.
* - p < 0.05; 
** - p < 0.01 - statistically significant differences in performance between the initial data and after 24 weeks of treatment.
the peak velocity of late filling (PVLF) was reduced by 5.7% 
and 2.7% respectively, in patients receiving the combined 
therapy - by 9.0%.  Modulus of elasticity (ME) and modulus 
of stiffness (MS) of the left ventricle decreased in group I by 
7.3% and by 11.8% respectively, in the II-nd - by 3.9% and 5.9% 
respectively, in the III-rd - by 11.9% and 15.6% respectively.
The effect of Losartan, Enalapril and their combination 
on morphofunctional parameters of the heart expressed in 
decreasing the size of the left heart chambers.  End systolic 
dimension (ESD) of the left ventricle before treatment with 
Losartan was 5.24 ± 0.67 cm, after 24 weeks of treatment – 
5.10 ± 0.71 cm (p > 0.1), with Enalapril – 5.47 ± 0.43 and 
5.25 ± 0.48 cm before and after treatment, respectively (p > 
0.1), with the combination of drugs – 5.16 ± 0.24 and 4.98 
± 0.25 cm, respectively (p > 0.1).  End diastolic dimension 
(EDD) before treatment with losartan was 6.4 ± 0.7 cm, with 
Enalapril – 6.52 ± 0.5 and 6.32 ± 0.7 cm with combination of 
drugs, after 24 weeks of treatment being 6.38 ± 0.8 cm, 6.56 
± 0.7 cm and 6.18 ± 0.5 cm, respectively (p < 0.05; p < 0.05; 
p < 0.05 respectively).
Indicators of cardiac remodeling in patients with CHF 
before and after treatment are presented in tab. 4.
The data in tab. 4 show that the use of combined therapy, 
which consisted of Losartan and Enalapril, provides a more 
favorable effect on the remodeling of the heart than their use 
in monotherapy.  We found significant positive dynamics of 
parameters reflecting LV remodeling: LVMMI decrease by 
15.6% with a 13.3% decrease RWT (tab. 4).
According to the bicycle stress test, the total amount of 
work performed by patients with CHF increased by 36.2% 
under the influence of Losartan, by 31.8% - of Enalapril and 
by 38.4% under treatment with both drugs.
The tolerance to drugs in all 3 groups was good. In pa-
tients from group I, transient hypotension was observed in 
7.7% of cases, which required short-term reduction of the 
dose, but not cancellation of the administration.  In patients 
from group II, side effects such as dry cough and transient 
hypotension were encountered during the observation period. 
This required a reduction in the dose of Enalapril in 11.1% of 
cases.  Side effects were observed in 7.4% cases of the III group. 
Discontinuation of the drug was not required in any case.
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Rolul pivotal al macrofagelor în progresia tumorală
V. Mazuru
Catedra Histologie, Citologie şi Embriologie, USMF “Nicolae Testemiţanu”
The Pivotal Role of Macrophages in Tumoral Progression
Clinical and experimental evidence have shown that macrophages (TAM) are the main component of the leukocyte infiltrate supporting 
tumor growth.  Over the years the mechanisms that support the tumor growth have become increasingly clear and in several experimental 
tumor models, the activation of an inflammatory response mediated by macrophages has been shown to play an essential role for full neoplastic 
transformation and progression.  TAMs are derived from peripheral blood monocytes recruited into the tumor.  Upon being activated by cancer 
cells, TAMs can release a vast diversity of growth factors, proteolytic enzymes, cytokines and inflammatory mediators.  Many of these agents are 
key factors in cancer progression.  The presence of extensive TAM infiltration has been shown to correlate with poor prognosis in a variety of 
human carcinomas. TAMs promote cancer progression through several mechanisms including the growth of tumor cells, tumor angiogenesis and 
lymphangiogenesis, matrix remodeling, tumor cell migration and invasion.  There are complex paracrine-signaling networks between TAMs and 
cancer cells to activate each other.  This evidence strongly supports the idea that TAMs are one of the most important players in the inflammatory 
networks expressed in the tumor microenvironment, and it suggests these cells as possible targets of anticancer therapies.
Key words: macrophages, tumor growth, tumoral microenvironment, metastasis, angiogenesis, lymphangiogenesis.
Главенствующая роль макрофагов в прогрессии опухолевого процесса
Результаты многочисленных клинических и экспериментальных исследований доказали что макрофаги являются самой 
многочисленной клеточной популяцией лейкоцитарного инфильтрата, поддерживающего опухолевый рост.  Со временем, различные 
механизмы через которые реализуется эта поддержка, стали хорошо изучены.  В экспериментальных опухолевых моделях было 
доказано, что воспалительная реакция, опосредованная макрофагами, играет огромную роль в полной неопластической трансформации 
и прогрессировании опухолевого процесса.  Макрофаги являются производными клетками моноцитов крови.  Под воздействием 
активации опухолевыми клетками, макрофаги способны синтезировать широкую гамму факторов роста, протеолитических ферментов, 
цитокинов и медиаторов воспаления.  Многие из этих веществ свидетельствуют об опухолевой прогрессии.  Было доказано, что высокая 
Treatment measurements had a positive impact on the 
dynamics of basic indicators of quality of life in patients of all 
3 groups.  Thus, in patients treated with Losartan, physical ac-
tivity and load and overall health have increased on average by 
21.5%, 28.7% and 15.4% respectively, while in patients treated 
with Lisinopril these have improved only by 6.2%, 11.1% and 
6.3%, respectively.  Patients treated with the combined therapy 
had a better increase of physical activity and load and overall 
health – by 28.7%, 35.4% and 27.3%, respectively.
Conclusions
Angiotensin receptor antagonist Losartan is an effective 
drug in the treatment of CHF, providing cardioprotective 
effect and good tolerability.
The use of combination therapy, including Losartan and 
Enalapril, leads to a more pronounced reduction of clinical symp-
toms of CHF compared with losartan or Enalapril monotherapy.
Effects of Losartan, Enalapril and their combination on 
the functional parameters of the heart expressed in a decre-
ase in the size of the left heart chambers and an increase in 
contractile function of the left ventricle, which were more 
pronounced when using combined therapy.
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